World News | James Paton and Robert Langreth, Bloomberg | Tuesday June 7, 2022
A drug from AstraZeneca Plc and Daiichi Sankyo Co. extended the lives of patients with an advanced form of breast cancer by about six months in a late-stage trial that may widen the population of people who can benefit from the treatment.
www.ndtv.com